Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples